BCG-EVs
This vaccine comprises EVs derived from Mycobacterium bovis and Escherichia coli Nissle 1917. BCG-EVs carry multiple molecules, including known protective TB antigens. The EVs will be lyophilized to ensure physicochemical stability and eliminate the need for a cold chain. Owing to their acellular nature, the vaccine is suitable for infants and children, including those living…
Read MoreTri:ChAd:TB
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Read MorerBCG-LTAK63
rBCG-LTAK63 is an unmarked recombinant BCG strain expressing the subunit A of detoxified E. coli Heat-Labile Toxin (LTAK63) as adjuvant. rBCG-LTAK63 induced protection superior to standard BCG, through enhanced and regulated Th1/Th17 responses, and both early effector and long-term TRM cell responses with reduced lung inflammation and improved immunopathological control.
Read MoreSpore-FP1
Spore-FP1 is a subunit vaccine candidate consisting of inactivated Bacillus subtilis spores coated with the FP1 fusion protein and formulated with Poly(I:C) adjuvant. FP1 fusion protein comprises Ag85B, Acr/HspX and the N-terminal domain of HBHA antigen. It is intended as a mucosal boost vaccine in BCG-immunised hosts.
Read MoreMtbDsigH
The parental candidate is an isogenic mutant in Mtb CDC1551 gene Rv3223c (sigH). We have now generated multiple Mtb double and triple knock-out (DKO, TKO) strains including: DsigHDsecA2DsodA, DsigHDfbpADsapM, DsigHDleuCDpanCD, DsigHDmetA, DsigHDmce4EDmce4F, DsigHDfadD29, DsigHDhadC, DsigHDRv3683, DsigHDmce1A, DsigHDcobM.
Read More